Search

As if underlining the judges’ decision, Karolinska Development, founded by Hans Wigzell, has shone light in the financial gloom, closing a big funding round.

Science is about to get back into Washington’s good books – and not before time, says Science|Business’s Nuala Moran.

The prospect of a sub-$1,000 human genome sequence moved closer as Oxford Nanopore Technologies Ltd agreed a marketing deal with Illumina Inc for its low-cost sequencing technology.